+0.36%
Today
Loading 1D prices…
Company profile
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Sector
Health Care
Industry
In Vitro & In Vivo Diagnostic Substances
Exchange
Nasdaq
Display currency
USD
Location
Frankfurt am Main, Germany, United States
Employees
27
Fiscal year end
1231
CIK
1982708
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MYGNMyriad Genetics Inc. Common Stock | $396M | $824.5M | -44.39% | -$3.95 | +7.51% | Sell |
| TKNOAlpha Teknova Inc. Common Stock | $400M | $40.5M | -42.59% | -$0.32 | +4.78% | Buy |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | $129.3M | $4.1M | -1.24% | -$1.65 | +10.34% | Hold |
| ICCCImmuCell Corporation Common Stock | $90.6M | $27.6M | -3.76% | -$0.12 | +3.85% | Unrated |
| QDELQuidelOrtho Corporation Common Stock | $760.5M | $2.7B | -41.45% | -$16.69 | +2.97% | Sell |